RxDoctor Payments Data

Federico del Toro, MD

Internal Medicine · Lafayette, LANPI 1932118445

Payments from drug & device makers

$5,703in general payments, 2019–2025

Across 311 payments — averaging $18.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Vifor Pharma, Inc.$824
  • AstraZeneca$760
  • Amgen$647
  • Akebia Therapeutics Inc$583
  • Fresenius USA Marketing, Inc.$523
  • Calliditas Therapeutics US Inc.$509
  • plus $2K from 24 others

What the payments were for

  • Food & beverage$5,703100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,703 in reported general payments places this provider in the 85th percentile of 1,528 internal medicine providers in Louisiana.

See all internal medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$151,107
Medicare patients
471
Services billed
2,967

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide44$42,958
EliquisApixaban74$41,284
FarxigaDapagliflozin Propanediol50$37,038
LinzessLinaclotide54$30,811
Trelegy ElliptaFluticasone/Umeclidin/Vilanter24$16,916
JanuviaSitagliptin Phosphate20$14,770
XareltoRivaroxaban22$7,800
DapagliflozinDapagliflozin Propanediol14$6,898
Spiriva HandihalerTiotropium Bromide13$6,699
TradjentaLinagliptin12$6,682
Lantus SolostarInsulin Glargine,hum.Rec.Anlog44$4,615
SymbicortBudesonide/Formoterol Fumarate19$4,488
Humalog Kwikpen U-100Insulin Lispro16$4,267
Atorvastatin Calcium278$3,384
Memantine Hcl53$2,833

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Levemir$54$44,35756 claims
AstraZenecaFarxiga, Symbicort$760$41,52669 claims
Johnson & JohnsonXarelto$43$7,80022 claims
Boehringer IngelheimTradjenta$21$6,68212 claims
Sanofi-aventis U.S. LLCLantus$40$97112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,528 internal medicine providers in Louisiana.

Other internal medicine in Lafayette

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →